Our Pricing

Wegovy vs Ozempic vs Mounjaro: Complete Comparison Guide

If you're researching wegovy vs ozempic vs mounjaro UK comparison options, you're likely weighing three of the most effective prescription weight loss treatments available today. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these choices with transparent pricing, expert guidance, and discreet next-day delivery across the UK.

Understanding the Three Medications: Active Ingredients and Mechanisms

Wegovy and Ozempic both contain semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to regulate appetite and blood sugar levels [1]. The key difference lies in their licensed indications: Wegovy is MHRA-approved specifically for chronic weight management, whilst Ozempic holds a licence for type 2 diabetes treatment, though it's increasingly prescribed off-label for weight loss in the UK [2].

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK, activating both glucose-dependent insulinotropic polypeptide and GLP-1 pathways simultaneously [3]. This dual mechanism produces more pronounced effects on appetite suppression and metabolic regulation compared to single-pathway treatments.

All three are once-weekly subcutaneous injections administered via pre-filled pens, making them convenient alternatives to daily weight loss medications. Each requires a prescription from a UK-registered prescriber following clinical assessment to ensure suitability based on your BMI, medical history, and weight loss goals.

Clinical Efficacy: How Much Weight Loss Can You Expect?

In the landmark SURMOUNT-1 trial, patients taking the highest Mounjaro dose (15mg) achieved an average weight reduction of 22.5% over 72 weeks, with more than half of participants losing at least 20% of their initial body weight [3]. This represents the highest efficacy seen in any obesity medication trial to date.

Wegovy demonstrated impressive results in the STEP trials, with participants losing an average of 14.9% of their body weight over 68 weeks at the 2.4mg maintenance dose [1]. The STEP-1 trial showed that 86% of patients achieved at least 5% weight loss, and nearly one-third lost 20% or more.

Ozempic, whilst not primarily studied for weight loss, showed average reductions of 14-15% in clinical trials using higher doses, though most UK prescriptions remain at lower doses intended for diabetes management [2]. When prescribed off-label for weight loss, results can be comparable to Wegovy given they share the same active ingredient.

Factors Influencing Individual Results

Clinical trial averages provide guidance, but individual responses vary considerably based on adherence to lifestyle modifications, starting BMI, metabolic health, and genetic factors. Our superintendent pharmacist Tarun Kumar emphasises that these medications work best as part of a comprehensive programme including dietary changes and increased physical activity, not as standalone solutions.

Wegovy vs Ozempic vs Mounjaro UK Comparison: Side Effects and Tolerability

The most common side effects across all three medications are gastrointestinal: nausea, vomiting, diarrhoea, and constipation, typically most pronounced during dose escalation phases [1][3]. In clinical trials, approximately 44% of Mounjaro users reported nausea, compared to 44% for Wegovy and similar rates for Ozempic.

Tirzepatide's dual mechanism may produce slightly higher rates of GI side effects initially, but many patients find these symptoms diminish after the first 4-8 weeks as the body adapts [3]. Gradual dose titration, as prescribed by UK clinicians, helps minimise discomfort during the adjustment period.

Serious adverse events remain rare but include potential pancreatitis, gallbladder problems, and thyroid concerns. All three medications carry similar contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Your UK prescriber will screen for these conditions during your clinical assessment.

Managing Common Side Effects

Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce nausea and digestive discomfort. If side effects persist or worsen, your prescriber may adjust your dose or recommend an alternative treatment from our weight loss range.

Dosing Schedules and Treatment Protocols

Wegovy follows a five-step dose escalation over 16-20 weeks, starting at 0.25mg weekly and increasing monthly to the maintenance dose of 2.4mg. This gradual approach, validated in the STEP trials, optimises tolerability whilst building therapeutic effect [1].

Mounjaro uses a similar titration strategy, beginning at 2.5mg weekly and increasing every four weeks up to a maximum of 15mg, though many patients achieve their weight loss goals at intermediate doses of 7.5mg or 10mg [3]. The flexibility in dosing allows prescribers to balance efficacy against side effects for each individual.

Ozempic typically starts at 0.25mg weekly for four weeks, then 0.5mg, with potential increases to 1mg or 2mg depending on response and tolerability. When used off-label for weight loss, some UK prescribers may escalate to higher doses, though this remains outside the medication's primary licence.

Cost Comparison and Value for Money in the UK

At Cured Pharmacy, Mounjaro starts from £135.00 per month, positioning it as a premium option that reflects its superior clinical efficacy in trials. Wegovy is available from £135.00 offering excellent value given its proven weight loss results and specific licensing for obesity treatment.

Pricing varies based on your prescribed dose, treatment duration, and current stock availability across UK pharmacies. We guarantee transparent upfront pricing before your consultation, with no hidden fees or surprise charges at checkout.

When evaluating cost-effectiveness, consider the percentage of body weight lost per pound spent, treatment duration required to reach your goal weight, and potential long-term health benefits including reduced cardiovascular risk and improved metabolic markers. Our clinical team can discuss these factors during your free online assessment.

Insurance and NHS Availability

NHS access to these medications remains limited, with strict eligibility criteria typically requiring BMI over 35 with comorbidities or BMI over 40, plus completion of specialist weight management programmes. Most UK patients access these treatments privately through registered online pharmacies like Cured Pharmacy, where clinical assessment can be completed in under three minutes.

Which Treatment Is Right for You? Clinical Recommendations

For patients seeking maximum weight loss potential and willing to invest in the most efficacious option available, Mounjaro's dual-pathway mechanism offers the highest average reductions seen in clinical trials [3]. It represents the cutting edge of obesity pharmacotherapy in the UK.

Wegovy remains an excellent choice for those wanting a well-established, specifically licensed weight loss treatment with extensive safety data and proven cardiovascular benefits beyond weight reduction [4]. Its slightly lower cost compared to Mounjaro makes it accessible to more patients whilst still delivering substantial results.

Ozempic may suit patients with concurrent type 2 diabetes who can address both conditions simultaneously, though its off-label use for weight loss alone requires careful discussion with your prescriber about licensing implications and insurance coverage.

Your final choice should be guided by a UK-registered prescriber who can assess your complete medical history, current medications, weight loss goals, and budget. At Cured Pharmacy, our clinical team provides personalised recommendations based on these individual factors, ensuring you receive the most appropriate treatment for your circumstances. All prescription medications require online clinical assessment before dispensing, in accordance with MHRA and GPhC regulations.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to lifestyle modifications alongside pharmacotherapy.